RTW backs Nuance Pharma – RTW Venture Fund backed Nuance Pharma in its $181 million Series D financing round, which was co-led by the fund’s investment manager RTW Investments, LP.
Nuance is a Chinese-based privately held fully integrated pharmaceutical company engaged in creating value through China’s specialty pharmaceutical markets, with an established focus on iron deficiency, pain management and respiratory conditions. Nuance plans to use the proceeds from the financing round to advance ongoing research and development of Nuance’s existing products and business development of potential new assets.
This represents RTW’s eleventh portfolio company addition in 2020, bringing the total number of companies in its core portfolio to eighteen.